
|Videos|July 27, 2015
What Pharmacists Should Prepare Patients for When Taking Weight-Loss Medications
Advertisement
Episodes in this series

Pharmacists can help set realistic expectations for patients taking weight-loss medications, according to Jennifer L. Costello, PharmD, BCPS, BC-ADM, ambulatory care clinical pharmacist at Saint Barnabas Medical Center.
For most weight-loss treatments, patients in clinical trials saw an average weight loss of 5% to 10% of their body weight. These results were seen among patients who were, concurrently, adhering to calorie-restricted diets and exercise regimens of 150 minutes per week.
Advertisement
Related to this article

Pharmacists can help identify uncontrolled risk factors, review medications, and reinforce when patients should seek emergency care.

The anti-CD20 antibody is the first drug approved specifically for the disease, based on phase 3 MAJESTY data showing higher remission vs tacrolimus.

In an interview with Pharmacy Times, Thomas Hope, MD, explains how earlier consideration of peptide receptor radionuclide therapy in neuroendocrine tumors makes treatment scheduling and continuity of care essential opportunities for pharmacists.

From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.

Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.

Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Structured Blood Glucose Testing: Why Timing Matters
2
Glucose Monitoring: Timing Makes Every Reading Count
3
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5









